Results 171 to 180 of about 48,469 (263)

Patient-reported time toxicity with bispecific antibody therapies in relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma. [PDF]

Oncologist
Major A, Ma E, Masaquel A, Tsang M, Di M, Kaur S, Pophali P, Werner S, Bungay R, Latrémouille-Viau D, Guerin A, Reyes C, Wu M, Cassoli L, Torka P.   +14 more
europepmc   +1 more source

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications

Head &Neck, Volume 48, Issue 8, Page 2180-2189, August 2026.
ABSTRACT Background Beyond follicular‐derived thyroid carcinomas, lymphomas, and metastatic disease, there are rare pathologies of the thyroid gland that represent a challenge. We report patients with unusual malignancies that mimic similar aggressive cancers. Methods Retrospective case series.
David Z. Allen, S. Mohsen Hosseini, Mark Zafereo, Miriam Lango, Elizabeth Gardner Grubbs, Priyanka Iyer, Shreyaskumar R. Patel, Vinod Ravi, Naifa Lamki Busaidy, Rui Jennifer Wang, Michelle D. Williams, Maria E. Cabanillas, Anastasios Maniakas   +12 more
wiley   +1 more source

Case Report: Extranodal marginal zone B-cell lymphoma in the lateral ventricle: literature review. [PDF]

Front Oncol
Xue Y, Li Z, Cui Y, Li G, Chang Q, Jia C, Du J.   +6 more
europepmc   +1 more source

First‐line treatment with epcoritamab in combination with bendamustine plus rituximab induces sustained remissions beyond 3 years in patients with follicular lymphoma

HemaSphere, Volume 10, Issue 8, August 2026.
Abstract First‐line (1L) bendamustine plus rituximab (BR) leads to high response rates in follicular lymphoma (FL), but maintaining durable remissions remains challenging. We report the 3‐year follow‐up from arm 3 of the phase 1b/2 EPCORE NHL‐2 trial (NCT04663347) of epcoritamab, a subcutaneously administered CD3×CD20 bispecific antibody, combined with
Umberto Vitolo, Lorenzo Falchi, Per‐Ola Andersson, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Jacob H. Christensen, Michael R. Clausen, Alexander Fosså, Pilar G. Prieto, Eliza A. Hawkes, Judit M. Jørgensen, Yasmin H. Karimi, Catharina Lewerin, Joost S. P. Vermaat, Björn E. Wahlin, Poliana Patah, Christopher Morehouse, Malene Risum, Zhu Li, Jennifer Marek, Joshua D. Brody   +21 more
wiley   +1 more source

Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component. [PDF]

Am J Clin Pathol
Zhao Y, Hajjali I, Ju Y, Carrillo L, Feng M, Dong Q, Chen D, Siddiqi I, Wang E.   +8 more
europepmc   +1 more source

Reversal of Cerebral Glucose Hypometabolism in a Patient with COVID and Refractory B-Cell Lymphoma. [PDF]

Int Med Case Rep J
Decosma L, Wolf E, Parent EE, Tun HW.
europepmc   +1 more source

Clinicopathological Features of Lupus Erythematosus Panniculitis (LEP): A Retrospective Analysis of 54 Cases

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background Lupus Erythematosus Panniculitis (LEP) is a rare subtype of Cutaneous Lupus Erythematosus. It is a challenging disease to diagnose and treat due to limited understanding of its clinical and histopathological characteristics. Methods We conducted a retrospective review of 54 biopsy‐proven LEP cases evaluated at a dermatology referral
Maryam Nasimi, Narjes Ramezani, Kambiz Kamyab, Alireza Abdshah, Maryam Ghiasi, Sahar Montazeri, Hanie Babaie, Fatemeh Saberi   +7 more
wiley   +1 more source

Clinical implications of endoscopic phenotypes in primary small intestinal lymphoma. [PDF]

Clin Endosc
Lee YJ.
europepmc   +1 more source

The Therapeutic Potential of Stem Cell Therapy for Doxorubicin‐Induced Cardiotoxicity: A Narrative Review

Health Science Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Background and Aims Doxorubicin (DOX) is a potent anthracycline chemotherapeutic agent whose clinical utility is significantly constrained by severe side effects, most notably DOX‐induced cardiotoxicity (DIC). Pathophysiological mechanisms of DIC include oxidative stress, mitochondrial dysfunction, programmed cell death, and inflammation ...
Ali Mirzaei, Pouria Rezaei, Reza Golchin Vafa, Saleheh Jahani, Reza Arefnezhad, Hossein Fatemian, Mohammad Hossein Nikoo, Amirhossein Sahebkar, Fatemeh Rezaei‐Tazangi   +8 more
wiley   +1 more source

Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy vs. CD20xCD3 bispecific antibody as third- or later-line treatment in follicular lymphoma: a meta-analysis. [PDF]

Ann Hematol
Li X, Liao J, Liu S, Mo X, Wang B.
europepmc   +1 more source